文 献1）がん・統計白書－罹患／死亡／予後－1999. 篠原出版新社編2）がん登録・統計[database on the internet].がん情報サービス 2016年7月7日 http://ganjoho.jp/reg_stat/statistics/stat/summary.html3）Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase Ⅲ; trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-8.4）Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, et al. Phase Ⅲ; trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 2231-7.5）Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase Ⅲ; trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28: 3617-22.6）Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-703.7）Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, Omuro Y, et al. PhaseⅠ/Ⅱstudy of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 2016; 77: 595-603.8）Moore MJ, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phaseⅢ trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. ASCO 2005.遠隔転移を有する高齢者膵癌に対する標準用量と低用量ゲムシタビン+ナブパクリタキセル併用療法のランダム化第Ⅱ相試験9）Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-25.10）Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial. J Clin Oncol 2011; 29: 4548-54.11）Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-8.12）Sakamoto H, Kitano M, Suetomi Y, Takeyama Y, Ohyanagi H, Nakai T, et al. Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial. J Gastroenterol 2006; 41: 70-6.13）Kang J, Hwang I, Yoo C, Kim KP, Jeong JH, Chang HM, et al. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Invest New Drugs 2018; 36: 732-41.14）Ishimoto U, Kinoshita A, Hirose Y, Shibata K, Ishii A, Shoji R, et al. The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients. Cancer Chemother Pharmacol 2019; 84: 647-54.15）Petrioli R, Torre P, Pesola G, Paganini G, Paolelli L, Miano ST, et al. Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer. J Geriatr Oncol 2019; 19: 30130-4.49
元のページ ../index.html#63